SHANGHAI HENLIUS BIOTECH, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 18.84 HKD | +4.67% |
|
-.--% | +35.54% |
| May. 24 | Organon, Henlius' Denosumab Biosimilar HLX14 Gets European Validation | MT |
| May. 24 | Henlius' EU Marketing Application for Denosumab Biosimilar Accepted and Validated by Regulator | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Sector Biopharmaceuticals
| Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E ratio | |
|---|---|---|---|---|---|---|
| 1.31B | - | - | ||||
| 89.87B | ||||||
| 37.57B | ||||||
| 32.75B | ||||||
| 26.47B | ||||||
| 14.25B |
